This propensity score–matched analysis uses National Cancer Database data on patients with gastroesophageal adenocarcinoma who received preoperative chemoradiotherapy and resection to explore whether adjuvant chemotherapy confers a survival benefit compared with observation.
This phase 2 clinical trial evaluated the safety and efficacy of individualized adaptive stereotactic body radiotherapy for liver tumors in patients who have preexisting liver dysfunction.
This longitudinal study tests the hypothesis that the secondary cancers developing in patients with Kaposi sarcoma have changed in recent years and assesses the risk of secondary cancers after Kaposi sarcoma in different periods using the Surveillance, Epidemiology, and End Results (SEER) program data.
This multicenter clinical study evaluates outcomes in different age groups among older patients with de novo acute myeloid leukemia who received HLA-mismatched microtransplant.
This SEER-Medicare database study of patients with colorectal, breast, prostate, or bladder cancer compares mortality between those who began therapy with statins within 6 months after cancer diagnosis and those who did not by emulating a trial free of selection bias.
This cohort study evaluates the effect of fiber intake after diagnosis on survival of patients with colorectal cancer.
This study determines whether survival was affected by more stringent definitions of pathologic nodal staging quality in a cohort of patients with non–small cell lung cancer who underwent resection with curative intent.
This study determines whether 70-gene signature assay findings are associated with physicians’ adjuvant treatment recommendations among patients with early breast cancer.
This phase 2 randomized clinical trial examines whether intervening with noninvasive stereotactic ablative radiotherapy prior to maintenance chemotherapy in patients with nonprogressive limited metastatic non–small-cell lung cancer after induction therapy led to significant improvements in progression-free survival.
This cohort study compares rates of adverse pathologic findings among very low-risk, low-risk, and low-volume intermediate-risk men electing immediate radical prostatectomy and evaluates criteria to define if a favorable intermediate-risk group minimizing risk exists.
This clinical trial of pembrolizumab in combination with metronomic cyclophosphamide assesses the efficacy and safety of PD-1 targeting in combination with metronomic chemotherapy in sarcomas.
This study addressed toxic effects and time to treatment failure in patients with melanoma treated with nivolumab plus ipilimumab.
This study uses data from the Veterans Affairs database to examine the association of HIV status with outcomes in patients with anal cancer.
This analysis uses SEER Medicaid data to quantify changes in health insurance coverage under the Affordable Care Act among nonelderly patients newly diagnosed with cancer.
This study evaluates the natural history of von Hippel–Lindau disease–associated pancreatic lesions to determine the factors associated with pancreatic neuroendocrine tumor phenotype and prognosis.
This study uses data from the National Cancer Database to examine the population-level efficacy of novel therapies for advanced-stage melanoma.
This observational study uses incidence rates before and after adoption of the Affordable Care Act (ACA) to assess whether adoption of the ACA increased screening for breast, colorectal, and cervical cancer.
This systematic review evaluates studies of oral chemotherapy safety and quality interventions.
A woman in her 50s receiving therapy for mantle cell lymphoma presented to the emergency department with acute, severe, left flank pain. What is your diagnosis?
This Viewpoint discusses the potential for reducing recurrence and mortality in patients with high-risk estrogen receptor–positive breast cancer by using an affordable intermittent salvage therapy.
This Viewpoint explores the possibility that data from published trials have been used to bolster the sales of a pemetrexed for use in nonsquamous non–small cell lung cancer.
This Viewpoint examines consideration of human epidermal growth factor receptor 2 as a biomarker in metastatic CRC.
This article provides a perspective on the effect of a diagnosis of cancer.
Create a personal account or sign in to: